Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL1904B CAR-T for Relapsed/Refractory B-ALL
NCT04546893Unknown
- Sponsor
- Senlang Bio
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Open-label, single-arm trial of sl1904b in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Status: unknown.
02
Drugs
sl1904b
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04546893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546893.